1. Medtech Insight
  2. >>Geography
  3. >>North America
  4. >>United States

Market Snapshot: Wireless/Telemetry Systems Drive Growth In Vital Signs Monitoring Space

The US market for vital signs monitoring equipment is expanding as hospitals increasingly move away from traditional, wired modular and portable monitoring systems to embrace the wireless monitoring trend that is enveloping health care today. Wireless telemetry monitoring is expected to post growth of more than 11%, compounded annually, according to Medtech Insight’s new report, “U.S. Markets, Trends, and Opportunities in Patient Monitoring Products.”

The US market for vital signs monitoring equipment is expanding at an overall rate of about 8% compounded annually; however, much higher growth is anticipated in the wireless/telemetry monitoring segment as hospitals increasingly move away from traditional, wired modular and portable monitoring systems to embrace the wireless monitoring trend that is enveloping health care today.

Wireless telemetry monitoring is expected to post growth of more than 11%, compounded annually, over the next several years, reaching...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Panel: FDA’s Home Healthcare Initiative Holds Promise, But Challenges Remain

 
• By Elizabeth Orr

During a recent FDLI panel, experts discussed the FDA's Home Healthcare initiative, highlighting its potential benefits and challenges. Key issues include usability testing, reimbursement, labeling for home use, and the need for innovation while ensuring patient safety.

J&J MedTech Launches KINCISE 2 Surgical Automated System In US

 
• By Natasha Barrow

The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 
• By Natasha Barrow

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.